ArticleScientific reports2025
Glucose-functionalized gold nanoparticles for effective photothermal therapy in lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials.Molecules (Basel, Switzerland) · 2026Review
- CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnoses that severely limit therapeutic interventions. In this context, nanoparticle-mediated photothermal therapy (PTT) has emerged as a promising and minimally toxic modality for solid tumors. We synthesized gold nanoparticles (AuNPs) with three distinct morphologies-spheres, rods, and stars-and functionalized them with polyethylene glycol (AuNPs-PEG) or polyethylene glycol conjugated with 2-deoxy-D-glucose (AuNPs-Gluc). In vitro analyses using human (A549, H1299) and murine (LLC) lung carcinoma cell lines demonstrated that PEGylation significantly attenuated AuNP-associated cytotoxicity, while glucose functionalization further enhanced biocompatibility. Inductively coupled plasma mass spectrometry quantification confirmed superior cellular uptake of AuNPs-Gluc compared to AuNPs-PEG (p < 0.05). Subsequent irradiation with a 980 nm diode laser (1 W) induced robust thermal damage and apoptotic cell death selectively in cancer cells treated with AuNPs-Gluc, sparing non-tumoral cells. Among the morphologies tested, star-shaped AuNPs exhibited the highest photothermal efficiency. In vivo experiments further substantiated the therapeutic potential, as combined administration of AuNPs-Gluc and laser irradiation significantly suppressed tumor growth (p < 0.01). Collectively, these findings highlight the utility of glucose-functionalized AuNPs as effective vectors for targeted PTT in lung cancer, supporting their translational relevance for future clinical applications in advanced-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.